Tags: Drug.

FCE 28260 is a 5-alpha-reductase inhibitor drug with antiandrogenic activity which was developed for the treatment of benign prostatic hyperplasia and androgenic (or androgenetic) alopecia in the 1990. Its current status is unknown.In a 1996 study FCE 28260 inhibited rat and human 5-alpha-reductase with half maximal inhibitory concentrations (IC50) of 15 and 16 nM respectively while finasteride had values of 30 and 52 nM.

FCE_28260_skeletal.svg
ATC prefix
none
IUPAC name
(4aR4bS6aS7S9aS9bS11aR)-4a6a-Dimethyl-2-oxo-N-((2RS)-111-trifluoro-2-phenyl-2-propanyl)-24a4b566a7899a9b101111a-tetradecahydro-1H-indeno[54-f]quinoline-7-carboxamide

Loading...

This page contains content from the copyrighted Wikipedia article "FCE 28260"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.